Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infantsGlobeNewsWire • 06/08/23
FDA advisers vote in favor of AstraZeneca, Sanofi antibody for infant RSV protectionMarket Watch • 06/08/23
US FDA staff flag no new safety issues for Sanofi-AstraZeneca's preventive RSV therapyReuters • 06/06/23
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosisGlobeNewsWire • 05/31/23
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of DirectorsGlobeNewsWire • 05/25/23
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of MedicineGlobeNewsWire • 05/21/23
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v SanofiPRNewsWire • 05/18/23
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In NewbornsInvestors Business Daily • 05/12/23
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial settingGlobeNewsWire • 05/12/23
Prescription-drug costs in spotlight as pharmacy benefit reform advances in SenateMarket Watch • 05/11/23
Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTSGlobeNewsWire • 05/04/23
Flatiron Health Embarks on Strategic Collaboration with Sanofi to Make Clinical Trials More Efficient by Streamlining Data Acquisition at the Point of CareBusiness Wire • 05/01/23
Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe DiseaseBusiness Wire • 05/01/23